Conditions: Refractory Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Intervention: Drug: Tisagenlecleucel
Sponsor: NeoImmuneTech
**RECRUITING NOW**
Intervention: Drug: Tisagenlecleucel
Sponsor: NeoImmuneTech
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
